NEW YORK (GenomeWeb) – Genomic Health announced today that national Medicare contractor Palmetto GBA has issued a favorable final local coverage determination expanding coverage of the company's Oncotype DX prostate cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.